Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8187MR)

This product GTTS-WQ8187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8187MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15112MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ5434MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ2579MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ584MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ9867MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ13734MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ9381MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ6553MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA D2E7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW